Key result
Mesenchymal stem cells possess immunomodulatory features and demonstrate potential in experimental models to reduce cardiac injury and improve cardiac function in inflammatory cardiomyopathy.
Mesenchymal stem cells offer a promising therapeutic strategy for inflammatory cardiomyopathy due to their immunomodulatory features and ability to home to the heart and improve myocardial function.
Answers are grounded in this paper and cite their sources.
Caution against routine MSC use in inflammatory cardiomyopathy; leaves open efficacy pending randomized trials.
Under conventional heart failure therapy, inflammatory cardiomyopathy usually has a progressive course, merging for alternative interventional strategies. There is accumulating support for the application of cellular transplantation as a strategy to improve myocardial function. Mesenchymal stem cells (MSCs) have the advantage over other stem cells that they possess immunomodulatory features, making them attractive candidates for the treatment of inflammatory cardiomyopathy. Studies in experimental models of inflammatory cardiomyopathy have consistently demonstrated the potential of MSCs to reduce cardiac injury and to improve cardiac function. This paper gives an overview about how inflammation triggers the functionality of MSCs and how it induces cardiac homing. Finally, the potential of intravenous application of MSCs by inflammatory cardiomyopathy is discussed.
No takes yet. Share an insight, caveat, or question.
Linthout et al. (2011) conducted a review in Inflammatory cardiomyopathy. Mesenchymal stem cells (MSCs) was evaluated. Mesenchymal stem cells possess immunomodulatory features and demonstrate potential in experimental models to reduce cardiac injury and improve cardiac function in inflammatory cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: